Share Price and Basic Stock Data
Last Updated: November 4, 2025, 6:55 pm
| PEG Ratio | -2.15 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chemcrux Enterprises Ltd operates in the specialty chemicals sector, focusing on niche markets. For the fiscal year ending March 2024, the company reported sales of ₹78.47 Cr, a decline from ₹95.15 Cr in the previous year. This trend illustrates a significant drop from the peak of ₹95.27 Cr in March 2022, reflecting challenges in maintaining revenue levels. Quarterly sales figures also showcased volatility, with the most recent quarter ending December 2023 reporting ₹21.81 Cr, down from ₹22.29 Cr in June 2023. This inconsistency in revenue generation highlights the company’s struggle to stabilize its sales amidst fluctuating market conditions. Historically, Chemcrux’s sales have seen substantial growth from ₹15.61 Cr in March 2014 to its peak in 2022, but the recent downward trend raises concerns about its market position and competitive dynamics. The company’s ability to adapt to changing market demands will be crucial for future growth.
Profitability and Efficiency Metrics
The profitability metrics of Chemcrux Enterprises Ltd reflect a challenging operational environment. The operating profit margin (OPM) reported for the fiscal year 2025 stood at 12.15%, a noticeable decline from 22.55% in 2023. This decline illustrates the pressure on margins due to rising costs or competitive pricing strategies. The net profit margin also faced a downturn, declining to 5.58% in March 2025 from 10.76% in March 2024. Return on equity (ROE) and return on capital employed (ROCE) are critical indicators of the company’s financial health, with ROE at 5.24% and ROCE at 7.01% for the fiscal year 2025, both significantly lower than historical highs of 21.62% and 25.13% respectively in 2023. The cash conversion cycle stood at 137.76 days, indicating inefficiencies in working capital management. These metrics suggest that while Chemcrux has historically performed well, current profitability and efficiency levels are under pressure, necessitating strategic improvements.
Balance Sheet Strength and Financial Ratios
Chemcrux Enterprises Ltd maintains a balance sheet that reflects a moderate level of financial stability. As of March 2025, total borrowings stood at ₹26.81 Cr against reserves of ₹61.30 Cr, indicating a reasonable leverage ratio and a total debt-to-equity ratio of 0.55. This ratio suggests that the company is utilizing debt judiciously, although an increase from 0.23 in March 2023 indicates a rising reliance on borrowed funds. The current ratio reported at 2.31 indicates a healthy liquidity position, allowing the company to cover its short-term liabilities comfortably. However, the interest coverage ratio of 6.14x, down from 17.48x in the previous year, signals a decline in the company’s ability to meet interest obligations from operating income. Overall, while Chemcrux’s balance sheet shows strength in terms of liquidity and reserves, increasing debt levels and declining coverage ratios warrant attention for potential financial risk management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemcrux Enterprises Ltd reveals a strong promoter backing, with promoters holding 72.92% of the shares as of March 2025. This level of promoter ownership can instill confidence among investors regarding the company’s long-term strategic direction. The public shareholding stands at 27.07%, a slight increase from previous periods, indicating a gradual diversification of ownership. The number of shareholders has decreased from 30,670 in June 2023 to 23,478 in March 2025, which may reflect investor sentiment towards the company’s recent performance. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests limited institutional interest, potentially raising concerns about market perception. Overall, while the strong promoter presence is a positive aspect, the declining number of shareholders and lack of institutional investment could affect long-term investor confidence.
Outlook, Risks, and Final Insight
The outlook for Chemcrux Enterprises Ltd hinges on its ability to navigate operational challenges and stabilize its revenue streams. The recent decline in sales and profitability may pose risks to its market position, especially in a competitive chemicals sector. Key strengths include a solid promoter backing and adequate liquidity, which could provide the necessary support for strategic initiatives. However, risks associated with rising debt levels, declining profitability margins, and the absence of institutional investors could hinder growth prospects. To mitigate these risks, Chemcrux must focus on enhancing operational efficiencies, optimizing its cost structure, and exploring new market opportunities. Should the company successfully implement strategic changes, it may regain its growth trajectory; conversely, failure to address these challenges could result in further declines in performance and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemcrux Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 479 Cr. | 52.3 | 86.7/42.6 | 29.2 | 20.0 | 0.77 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 36.5 Cr. | 74.4 | 104/56.0 | 16.3 | 87.4 | 1.34 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.0 Cr. | 720 | 1,178/600 | 53.2 | 670 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,686 Cr. | 81.3 | 114/78.0 | 24.6 | 20.7 | 0.62 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 755 Cr. | 302 | 453/241 | 27.1 | 91.1 | 0.83 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,748.80 Cr | 729.54 | 47.83 | 178.98 | 0.41% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 26.66 | 26.90 | 27.74 | 20.50 | 20.01 | 22.29 | 15.84 | 21.81 | 18.54 | 17.11 | 17.76 | 19.42 | 15.97 |
| Expenses | 20.24 | 21.38 | 21.94 | 15.47 | 14.90 | 18.43 | 13.50 | 17.43 | 15.92 | 15.05 | 15.40 | 16.73 | 14.03 |
| Operating Profit | 6.42 | 5.52 | 5.80 | 5.03 | 5.11 | 3.86 | 2.34 | 4.38 | 2.62 | 2.06 | 2.36 | 2.69 | 1.94 |
| OPM % | 24.08% | 20.52% | 20.91% | 24.54% | 25.54% | 17.32% | 14.77% | 20.08% | 14.13% | 12.04% | 13.29% | 13.85% | 12.15% |
| Other Income | 0.10 | 0.24 | 0.32 | 0.31 | 0.18 | 0.18 | 0.24 | 0.56 | 0.35 | 0.39 | 0.26 | 0.61 | 0.28 |
| Interest | 0.06 | 0.15 | 0.13 | 0.07 | 0.47 | 0.31 | 0.21 | 0.17 | 0.13 | 0.13 | 0.33 | 0.60 | 0.58 |
| Depreciation | 0.41 | 0.44 | 0.48 | 0.54 | 0.58 | 0.57 | 0.58 | 0.58 | 0.55 | 0.56 | 0.73 | 0.92 | 0.91 |
| Profit before tax | 6.05 | 5.17 | 5.51 | 4.73 | 4.24 | 3.16 | 1.79 | 4.19 | 2.29 | 1.76 | 1.56 | 1.78 | 0.73 |
| Tax % | 25.12% | 25.92% | 26.86% | 24.31% | 31.13% | 26.27% | 30.17% | 36.75% | 3.49% | 29.55% | 26.28% | 25.84% | 35.62% |
| Net Profit | 4.53 | 3.83 | 4.03 | 3.58 | 2.92 | 2.33 | 1.24 | 2.66 | 2.21 | 1.24 | 1.15 | 1.33 | 0.47 |
| EPS in Rs | 3.06 | 2.59 | 2.72 | 2.42 | 1.97 | 1.57 | 0.84 | 1.80 | 1.49 | 0.84 | 0.78 | 0.90 | 0.32 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemcrux Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 15.97 Cr.. The value appears to be declining and may need further review. It has decreased from 19.42 Cr. (Dec 2024) to 15.97 Cr., marking a decrease of 3.45 Cr..
- For Expenses, as of Mar 2025, the value is 14.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.73 Cr. (Dec 2024) to 14.03 Cr., marking a decrease of 2.70 Cr..
- For Operating Profit, as of Mar 2025, the value is 1.94 Cr.. The value appears to be declining and may need further review. It has decreased from 2.69 Cr. (Dec 2024) to 1.94 Cr., marking a decrease of 0.75 Cr..
- For OPM %, as of Mar 2025, the value is 12.15%. The value appears to be declining and may need further review. It has decreased from 13.85% (Dec 2024) to 12.15%, marking a decrease of 1.70%.
- For Other Income, as of Mar 2025, the value is 0.28 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Dec 2024) to 0.28 Cr., marking a decrease of 0.33 Cr..
- For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.60 Cr. (Dec 2024) to 0.58 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Mar 2025, the value is 0.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Dec 2024) to 0.91 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 1.78 Cr. (Dec 2024) to 0.73 Cr., marking a decrease of 1.05 Cr..
- For Tax %, as of Mar 2025, the value is 35.62%. The value appears to be increasing, which may not be favorable. It has increased from 25.84% (Dec 2024) to 35.62%, marking an increase of 9.78%.
- For Net Profit, as of Mar 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 1.33 Cr. (Dec 2024) to 0.47 Cr., marking a decrease of 0.86 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.32. The value appears to be declining and may need further review. It has decreased from 0.90 (Dec 2024) to 0.32, marking a decrease of 0.58.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | 69.90 |
| Expenses | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | 61.32 |
| Operating Profit | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 | 8.58 |
| OPM % | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% | 12.27% |
| Other Income | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | 1.76 |
| Interest | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 | 2.03 |
| Depreciation | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 | 3.51 |
| Profit before tax | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 | 4.80 |
| Tax % | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% | |
| Net Profit | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | 3.53 |
| EPS in Rs | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 | 2.39 |
| Dividend Payout % | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 97.67% | 104.71% | -13.79% | 57.33% | 294.92% | 14.16% | -16.07% | 66.41% | -3.36% | -41.23% | -50.36% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.03% | -118.50% | 71.13% | 237.58% | -280.75% | -30.23% | 82.48% | -69.77% | -37.86% | -9.13% |
Chemcrux Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 4% |
| 3 Years: | -10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -17% |
| 3 Years: | -35% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | -34% |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: July 25, 2025, 1:35 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 61.30 |
| Borrowings | 3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 26.81 |
| Other Liabilities | 4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 9.23 |
| Total Liabilities | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 |
| Fixed Assets | 6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 57.55 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 21.06 | 1.61 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 19.84 |
| Other Assets | 6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 33.15 |
| Total Assets | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 |
Below is a detailed analysis of the balance sheet data for Chemcrux Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.81 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.81 Cr..
- For Reserves, as of Mar 2025, the value is 61.30 Cr.. The value appears strong and on an upward trend. It has increased from 57.45 Cr. (Mar 2024) to 61.30 Cr., marking an increase of 3.85 Cr..
- For Borrowings, as of Mar 2025, the value is 26.81 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 26.46 Cr. (Mar 2024) to 26.81 Cr., marking an increase of 0.35 Cr..
- For Other Liabilities, as of Mar 2025, the value is 9.23 Cr.. The value appears to be improving (decreasing). It has decreased from 11.15 Cr. (Mar 2024) to 9.23 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2025, the value is 112.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 109.87 Cr. (Mar 2024) to 112.15 Cr., marking an increase of 2.28 Cr..
- For Fixed Assets, as of Mar 2025, the value is 57.55 Cr.. The value appears strong and on an upward trend. It has increased from 33.09 Cr. (Mar 2024) to 57.55 Cr., marking an increase of 24.46 Cr..
- For CWIP, as of Mar 2025, the value is 1.61 Cr.. The value appears to be declining and may need further review. It has decreased from 21.06 Cr. (Mar 2024) to 1.61 Cr., marking a decrease of 19.45 Cr..
- For Investments, as of Mar 2025, the value is 19.84 Cr.. The value appears strong and on an upward trend. It has increased from 19.83 Cr. (Mar 2024) to 19.84 Cr., marking an increase of 0.01 Cr..
- For Other Assets, as of Mar 2025, the value is 33.15 Cr.. The value appears to be declining and may need further review. It has decreased from 35.89 Cr. (Mar 2024) to 33.15 Cr., marking a decrease of 2.74 Cr..
- For Total Assets, as of Mar 2025, the value is 112.15 Cr.. The value appears strong and on an upward trend. It has increased from 109.87 Cr. (Mar 2024) to 112.15 Cr., marking an increase of 2.28 Cr..
Notably, the Reserves (61.30 Cr.) exceed the Borrowings (26.81 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.90 | -0.48 | -0.46 | -0.55 | 1.00 | 11.24 | 12.86 | 11.63 | 11.60 | 7.03 | -13.09 | -17.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 |
| Inventory Days | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 127.16 |
| Days Payable | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 70.84 | 52.84 |
| Cash Conversion Cycle | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 99.96 | 137.76 |
| Working Capital Days | 8.18 | 8.94 | 21.80 | 34.20 | 43.17 | 47.68 | 52.48 | 67.69 | 37.51 | 67.28 | 55.49 | 50.09 |
| ROCE % | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Diluted EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Cash EPS (Rs.) | 4.81 | 7.25 | 11.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Revenue From Operations / Share (Rs.) | 47.27 | 52.98 | 64.25 |
| PBDIT / Share (Rs.) | 7.24 | 9.82 | 15.20 |
| PBIT / Share (Rs.) | 5.07 | 8.28 | 13.82 |
| PBT / Share (Rs.) | 3.89 | 7.72 | 13.27 |
| Net Profit / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| NP After MI And SOA / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| PBDIT Margin (%) | 15.30 | 18.54 | 23.64 |
| PBIT Margin (%) | 10.72 | 15.62 | 21.50 |
| PBT Margin (%) | 8.22 | 14.56 | 20.64 |
| Net Profit Margin (%) | 5.58 | 10.76 | 15.08 |
| NP After MI And SOA Margin (%) | 5.58 | 10.76 | 15.08 |
| Return on Networth / Equity (%) | 5.24 | 11.68 | 21.62 |
| Return on Capital Employeed (%) | 7.01 | 12.65 | 25.13 |
| Return On Assets (%) | 3.08 | 7.68 | 14.49 |
| Long Term Debt / Equity (X) | 0.37 | 0.29 | 0.18 |
| Total Debt / Equity (X) | 0.55 | 0.35 | 0.23 |
| Asset Turnover Ratio (%) | 0.59 | 0.75 | 0.00 |
| Current Ratio (X) | 2.31 | 3.88 | 3.34 |
| Quick Ratio (X) | 1.81 | 3.23 | 2.54 |
| Inventory Turnover Ratio (X) | 7.60 | 2.25 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 37.84 | 35.07 | 20.62 |
| Dividend Payout Ratio (CP) (%) | 20.80 | 27.60 | 18.06 |
| Earning Retention Ratio (%) | 62.16 | 64.93 | 79.38 |
| Cash Earning Retention Ratio (%) | 79.20 | 72.40 | 81.94 |
| Interest Coverage Ratio (X) | 6.14 | 17.48 | 27.50 |
| Interest Coverage Ratio (Post Tax) (X) | 3.24 | 11.14 | 18.54 |
| Enterprise Value (Cr.) | 189.29 | 402.43 | 448.23 |
| EV / Net Operating Revenue (X) | 2.70 | 5.13 | 4.71 |
| EV / EBITDA (X) | 17.66 | 27.66 | 19.92 |
| MarketCap / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| Retention Ratios (%) | 62.15 | 64.92 | 79.37 |
| Price / BV (X) | 2.00 | 5.29 | 6.62 |
| Price / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| EarningsYield | 0.02 | 0.02 | 0.03 |
After reviewing the key financial ratios for Chemcrux Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.25 (Mar 24) to 4.81, marking a decrease of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.27. It has decreased from 52.98 (Mar 24) to 47.27, marking a decrease of 5.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.24. This value is within the healthy range. It has decreased from 9.82 (Mar 24) to 7.24, marking a decrease of 2.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 8.28 (Mar 24) to 5.07, marking a decrease of 3.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 7.72 (Mar 24) to 3.89, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For PBDIT Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 18.54 (Mar 24) to 15.30, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 10.72. This value is within the healthy range. It has decreased from 15.62 (Mar 24) to 10.72, marking a decrease of 4.90.
- For PBT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has decreased from 14.56 (Mar 24) to 8.22, marking a decrease of 6.34.
- For Net Profit Margin (%), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 8. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 11.68 (Mar 24) to 5.24, marking a decrease of 6.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.01. This value is below the healthy minimum of 10. It has decreased from 12.65 (Mar 24) to 7.01, marking a decrease of 5.64.
- For Return On Assets (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 5. It has decreased from 7.68 (Mar 24) to 3.08, marking a decrease of 4.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.29 (Mar 24) to 0.37, marking an increase of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.55, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has decreased from 0.75 (Mar 24) to 0.59, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has decreased from 3.88 (Mar 24) to 2.31, marking a decrease of 1.57.
- For Quick Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 3.23 (Mar 24) to 1.81, marking a decrease of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 7.60, marking an increase of 5.35.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.84. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 37.84, marking an increase of 2.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.80. This value is within the healthy range. It has decreased from 27.60 (Mar 24) to 20.80, marking a decrease of 6.80.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.16. This value is within the healthy range. It has decreased from 64.93 (Mar 24) to 62.16, marking a decrease of 2.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.20. This value exceeds the healthy maximum of 70. It has increased from 72.40 (Mar 24) to 79.20, marking an increase of 6.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.14. This value is within the healthy range. It has decreased from 17.48 (Mar 24) to 6.14, marking a decrease of 11.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 11.14 (Mar 24) to 3.24, marking a decrease of 7.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.29. It has decreased from 402.43 (Mar 24) to 189.29, marking a decrease of 213.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has decreased from 5.13 (Mar 24) to 2.70, marking a decrease of 2.43.
- For EV / EBITDA (X), as of Mar 25, the value is 17.66. This value exceeds the healthy maximum of 15. It has decreased from 27.66 (Mar 24) to 17.66, marking a decrease of 10.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For Retention Ratios (%), as of Mar 25, the value is 62.15. This value is within the healthy range. It has decreased from 64.92 (Mar 24) to 62.15, marking a decrease of 2.77.
- For Price / BV (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.29 (Mar 24) to 2.00, marking a decrease of 3.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemcrux Enterprises Ltd:
- Net Profit Margin: 5.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.01% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 24.61%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 53.7 (Industry average Stock P/E: 41.85)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 330, Trivia Complex, Vadodra Gujarat 390007 | celbaroda3821@gmail.com http://www.chemcrux.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Girishkumar C Shah | Executive Chairman |
| Mr. Sanjay Marathe | Managing Director |
| Mr. Vipul Sanghvi | Executive Director |
| Mr. Sidhdhi G Shah | Non Executive Director |
| Mr. Shailesh Patel | Independent Director |
| Mr. Bhanubhai Patel | Independent Director |
| Mr. Nayankumar Shah | Independent Director |
| Mr. Rohit Kothari | Independent Director |
FAQ
What is the intrinsic value of Chemcrux Enterprises Ltd?
Chemcrux Enterprises Ltd's intrinsic value (as of 04 November 2025) is 119.28 which is 6.81% lower the current market price of 128.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 189 Cr. market cap, FY2025-2026 high/low of 205/100, reserves of ₹61.30 Cr, and liabilities of 112.15 Cr.
What is the Market Cap of Chemcrux Enterprises Ltd?
The Market Cap of Chemcrux Enterprises Ltd is 189 Cr..
What is the current Stock Price of Chemcrux Enterprises Ltd as on 04 November 2025?
The current stock price of Chemcrux Enterprises Ltd as on 04 November 2025 is 128.
What is the High / Low of Chemcrux Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemcrux Enterprises Ltd stocks is 205/100.
What is the Stock P/E of Chemcrux Enterprises Ltd?
The Stock P/E of Chemcrux Enterprises Ltd is 53.7.
What is the Book Value of Chemcrux Enterprises Ltd?
The Book Value of Chemcrux Enterprises Ltd is 51.4.
What is the Dividend Yield of Chemcrux Enterprises Ltd?
The Dividend Yield of Chemcrux Enterprises Ltd is 0.78 %.
What is the ROCE of Chemcrux Enterprises Ltd?
The ROCE of Chemcrux Enterprises Ltd is 7.11 %.
What is the ROE of Chemcrux Enterprises Ltd?
The ROE of Chemcrux Enterprises Ltd is 5.36 %.
What is the Face Value of Chemcrux Enterprises Ltd?
The Face Value of Chemcrux Enterprises Ltd is 10.0.